To support a potential role in cancer, we first explored clinical datasets, observing that both HECTD4 mRNA and protein expression are considerably reduced in primary and metastatic breast cancers, compared with normal breast tissue (Fig. 1E and SI Appendix, Fig. S1A) (15). This evidence concerns the gene HECTD4 and breast cancer.